We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

115 hedge funds and large institutions have $271M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $570K | Put options by funds: $180K

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

11% more capital invested

Capital invested by funds: $243M → $271M (+$27.7M)

12% less funds holding

Funds holding: 130 → 115 (-15)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

56% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 25

Holders
115
Holders Change
-15
Holders Change %
-11.54%
% of All Funds
2.01%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
11
Increased
44
Reduced
35
Closed
25
Calls
$570K
Puts
$180K
Net Calls
+$390K
Net Calls Change
+$1.78M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$12.4M
2
RI
RTW Investments
New York
+$8.65M
3
PHS
PFM Health Sciences
California
+$3.63M
4
Goldman Sachs
Goldman Sachs
New York
+$3.16M
5
O
OrbiMed
New York
+$3.15M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$10.8M
2
Victory Capital Management
Victory Capital Management
Texas
-$3.3M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.91M
4
TCM
Tekla Capital Management
Massachusetts
-$2.6M
5
CS
Credit Suisse
Switzerland
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.79M -$1.34M -217,091 -47%
Two Sigma Investments
27
Two Sigma Investments
New York
$1.66M -$463K -74,726 -25%
Assenagon Asset Management
28
Assenagon Asset Management
Luxembourg
$1.58M -$2.91M -469,827 -69%
SCM
29
Silverarc Capital Management
Massachusetts
$1.55M -$261K -42,085 -17%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$1.5M +$96.9K +15,636 +8%
Wells Fargo
31
Wells Fargo
California
$1.42M +$290K +46,815 +32%
N
32
Nuveen
North Carolina
$1.3M +$70K +11,299 +7%
GIM
33
Granahan Investment Management
Massachusetts
$1.29M -$1.14M -183,642 -51%
Marshall Wace
34
Marshall Wace
United Kingdom
$1.26M -$507K -81,792 -33%
AQR Capital Management
35
AQR Capital Management
Connecticut
$1.24M +$69.6K +11,240 +7%
CS
36
Credit Suisse
Switzerland
$1.23M -$2.38M -384,699 -70%
Mariner
37
Mariner
Kansas
$1.11M +$50 +8 +0%
Charles Schwab
38
Charles Schwab
California
$1.07M -$709K -114,507 -44%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$952K +$160K +25,811 +25%
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$898K +$299K +48,302 +67%
SSA
41
Schonfeld Strategic Advisors
New York
$867K -$81.9K -13,228 -10%
YMRC
42
Yorktown Management & Research Company
Virginia
$841K +$351K +56,600 +100%
PAM
43
Panagora Asset Management
Massachusetts
$785K +$79.5K +12,829 +14%
GCP
44
GSA Capital Partners
United Kingdom
$720K +$274K +44,277 +84%
PCM
45
Pathway Capital Management
California
$630K +$152K +24,484 +41%
ZCM
46
Ziegler Capital Management
Illinois
$511K -$14.4K -2,317 -3%
AllianceBernstein
47
AllianceBernstein
Tennessee
$460K – – –
JRP
48
Jasper Ridge Partners
California
$378K +$315K +50,858 New
Principal Financial Group
49
Principal Financial Group
Iowa
$342K -$10.8K -1,736 -4%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$316K +$7.23K +1,167 +3%
1
2
3 4 5

JNCE Hedge Fund Activity: Q3 2021 in Review

115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2021, worth a combined $271M — up 11% from $243M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of JNCE and 11 opened new positions — a net loss of 14 holders — while 35 trimmed existing stakes and 44 added.

The largest buyer was Logos Global Management, opening a new position worth an estimated $12.4M. The largest seller was TRV GP II, cutting an estimated $10.8M.

  • 115 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2021, down from 130 in Q2 2021.
  • Funds reported $271M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2021, up 11% quarter-over-quarter.
  • 11 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2021 and 25 closed out, a net change of -14 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2021 was Logos Global Management, an estimated $12.4M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2021 was TRV GP II, an estimated $10.8M sold.

Based on aggregated 13F filings for Q3 2021.